Peptides and Fatty Liver / NASH: Research on Hepatoprotection
Written by NorthPeptide Research Team | Reviewed January 2, 2026
NAFLD and NASH: A Growing Research Priority
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in people who drink little or no alcohol. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which involves inflammation, cell damage, and can progress to fibrosis, cirrhosis, and liver failure. NAFLD affects approximately 25% of the global adult population, making it one of the most prevalent liver conditions and a high-priority area for research.
BPC-157 and Fatty Liver Research
BPC-157 has shown hepatoprotective effects in multiple animal models. In studies examining alcohol-induced liver damage and toxin-induced steatosis, BPC-157 administration consistently reduces markers of liver injury including ALT and AST, decreases hepatic inflammation, and preserves liver architecture.
The mechanisms proposed include: modulation of nitric oxide pathways, upregulation of growth factor receptors (particularly EGF-R), reduction of oxidative stress, and direct cytoprotective effects on hepatocytes. Some researchers have also noted that BPC-157 appears to have effects on gut-liver axis signaling, which is relevant given the emerging understanding of how gut dysbiosis contributes to NAFLD progression.
All BPC-157 fatty liver research has been preclinical. No human trials have been conducted for NAFLD or NASH indications.
Glutathione and Oxidative Stress in NAFLD
Oxidative stress plays a central role in the progression from simple NAFLD to NASH. When hepatocytes accumulate excess fat, mitochondrial dysfunction increases reactive oxygen species (ROS) production. If the liver’s endogenous antioxidant capacity — primarily glutathione — is overwhelmed, oxidative damage drives inflammation and cell death.
A randomized controlled trial by Honda et al. (2017) found that oral glutathione supplementation significantly reduced ALT levels in NAFLD patients over 4 months. This represents one of the stronger human-level signals in this space, though bioavailability of oral glutathione remains a challenge.
The Gut-Liver Axis
A growing body of research connects gut microbiome health to NAFLD progression. The gut and liver are linked via the portal vein — bacterial products, short-chain fatty acids, and inflammatory signals from the gut reach the liver directly. Peptides like BPC-157 that have been shown to modulate gut barrier function and reduce intestinal permeability may therefore have indirect liver benefits by reducing the endotoxin load reaching the liver.
Research Gaps and Cautions
The field suffers from a consistent problem: positive findings in rodent NAFLD models have historically not translated reliably to human clinical benefit. Many compounds have shown hepatoprotection in mice that failed in human trials. Additionally, NAFLD and NASH have multifactorial causes — metabolic syndrome, insulin resistance, genetics, gut microbiome — and no single peptide is likely to address all contributing factors.
Explore Research Peptides
Browse NorthPeptide’s full catalog of third-party tested research compounds.
Written by the NorthPeptide Research Team
| PMID | Authors | Year | Key Finding |
|---|---|---|---|
| 26721569 | Honda Y et al. | 2017 | Oral glutathione supplementation reduces ALT in NAFLD patients: RCT |
| 23093478 | Sikiric P et al. | 2012 | BPC-157 hepatoprotective effects in models of liver injury |
| 28167872 | Gariani K et al. | 2016 | NAD+ repletion reverses fatty liver disease in rodent models |
| 24393403 | Pappachan JM et al. | 2017 | NAFLD: pathogenesis, diagnosis, and treatment overview |
| 29321194 | Younossi ZM et al. | 2018 | Global epidemiology of NAFLD: trends, predictions, risk factors |
This content is intended for informational purposes only and is not medical advice. NorthPeptide products are for laboratory research use only and are not approved for human consumption. Always consult a qualified healthcare professional.